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Prevention of the Influence of Fibrin and
a2-Macroglobulin in the Continuous Measurement
of the Thrombin Potential: Implications for an
Endpoint Determination of the Optical Density
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amidolytic activity and this would imply that mea-Abstract
surement of the ETP is reduced to an endpoint
determination of the optical density. We show thatWe proposed the endogenous thrombin potential
the endpoint determination of the optical density(ETP) as an overall function test of the coagulation
correlates well with the calculated ETP in plasmassystem. We recently introduced a routine test
with different degrees of anticoagulation.  1998which requires defibrinated plasma. In order to
Elsevier Science Ltd.develop an assay in which the ETP-value can be
directly obtained by measuring the optical density,
Key Words: Fibrin polymerization inhibitor; Hydroxyl-we investigated two methods to inhibit fibrinogen
amine; a2-macroglobulin; Snake venom; Thrombin genera-clottability and to inactivate a2-macroglobulin. The
tion assay; Thrombin potentialfirst method makes use of hydroxylamine to inacti-
vate a2-macroglobulin and H-Gly-Pro-Arg-Pro-
The time course of thrombin developing inOH to inhibit fibrin polymerization. At pH 7.35, a triggered plasma sample can be continu-plasma incubated with 25 mM hydroxylamine and ously monitored in a spectrophotometer. A1.5 mg/mL H-Gly-Pro-Arg-Pro-OH for 5 minutes
slow reacting but specific chromogenic substrate isat 378C resulted in a reduced endlevel of the ami-
added and the conditions are chosen such that thedolytic activity on small chromogenic substrates.
velocity of product formation is proportional toThe second method uses a metalloprotease purified
the concentration of the enzyme present. The firstfrom Crotalus basiliscus to remove a2-macroglobu-
derivative of the optical density signal renders thelin from plasma in combination with H-Gly-Pro-
time course of the amidolytic activity in the sample.Arg-Pro-OH. Herein plasma is incubated with 3.5
This method allows the measurement of the areamM protease during 15 minutes at 378C in the pres-
under the thrombin generation curve (endogenousence of 1 mg/mL polymerization inhibitor. The en-
thrombin potential, ETP) without subsampling [1].zymatic method results in a zero endlevel of the
In plasma, thrombin is mainly inhibited by anti-
thrombin III (AT-III) and a2-macroglobulin (a2M)
Abbreviations: ETP, endogenous thrombin potential. [2]. The reaction of free thrombin with a2M yields
Corresponding author: Dr. H.C. Hemker, Maastricht University, a complex (a2M-IIa) that has no known biologicalFaculty of Medicine, Department of Biochemistry, P.O. Box 616,
activity but retains amidolytic activity on small6200 MD Maastricht, The Netherlands; Tel: 131.43.3881675; Fax:
131.43.3670988. chromogenic substrates. The free thrombin curve
0049-3848/98 $19.00 1 .00  1998 Elsevier Science Ltd. Printed in the USA. All rights reserved.
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therefore is not identical to the amidolytic activity uous thrombin generation assay to inactivate a2M.
The enzymatic method results in a zero endlevelcurve and can only be obtained by mathematical
processing of the signal [3,4]. We tried to circum- of the amidolytic activity on small chromogenic
substrates. This implies that measuring the throm-vent this problem by synthesizing substrates that,
like the biological substrates, were too bulky to be bin potential is simplified to an endpoint determi-
nation of the optical density.hydrolyzed by a2M-IIa. Neither the introduction
of space demanding groups nor extending binding
interactions with thrombin (P5-P93 [5]) and the
1. Materials and Methodsfibrinogen recognition exosite [6,7] led to full selec-
tivity toward free thrombin only, even in a 18 amino
1.1. Reagentsacid substrate [8]. Alternatively we tried to inacti-
vate a2M before triggering the plasma [9].
The chromogenic substrate used in the continuousHuman a2M is a plasma glycoprotein that func-
thrombin generation experiments was 2-(methyl-tions as an unspecific protease inhibitor [10]. It
sulfonyl)ethyloxycarbonyl-valyl-arginine p-nitro-consists of four equal subunits of 180 kDa held
anilide monohydrochloride (Msc-Val-Arg-pNA)together by disulfide bridges. Each subunit con-
[8]. H-D-Phe-Pip-Arg-pNA (S2238) was used astains a protease sensitive region, the so-called bait
substrate to measure thrombin activity in subsam-region. When a protease splits a peptide bond in
pling experiments. The substrates were dissolvedthis region, a2M undergoes a conformational
in distilled water. The concentration was deter-change which makes it trap the protease [11]. The
mined at 316 nm using a molar extinction coeffi-hydrolysis exposes a nucleophile-sensitive b-cystei-
cient of 12,500 Lmol21cm21. Stock solutions werenyl-g-glutamyl thiol ester bond, which reacts with
stored in the dark at 48C. The fibrin polymerizatione-amino groups of lysine residues of the protease.
inhibitor H-Gly-Pro-Arg-Pro-OH (GPRP, Pefa-In this article we describe two methods to inacti-
bloct FG) was obtained from Pentapharm (Basel,vate a2M in human plasma exploiting its inhibition
Switzerland). Heparin (4th International Standardmechanism. First, native a2M is sensitive to small
nucleophiles such as methylamine (CH3-NH2) [12– Heparin) was obtained from the National Institute
14]. The methylamine-induced thiol ester cleavage for Biological Standards and Control (London,
results in a conformational change of a2M in which UK). Hydroxylamine was a 40% solution in water
it cannot bind a protease. Denaturation of a2M by and diluted in buffer A and was purchased from
methylamine is not suitable in plasma, due to its Fluka (Büchs, Switzerland). Small unilamellar
high basicity. Hydroxylamine (HO-NH2), however, phospholipid vesicles were prepared as described
is a weak base and extremely useful to aminolyse by Rosing et al. [20]. The vesicles composed of a
thiol esters [15] under neutral conditions. Protease mixture (on molar basis) of 1,2-dioleoyl-sn-gly-
binding capacity of hydroxylamine-treated a2M is cero-3-phosphocholine (DOPC) / 1,2-dioleoyl-sn-
significantly reduced but its applicability in plasma glycero-3-phospho-L-serine (DOPS) 80/20. The
was not studied [16]. phospholipids were obtained from Avanti Polar
Second, we describe an enzymatic method to in- Lipids Inc. (Alabaster, AL). Buffer A: 20 mM
activate a2M by means of a protease from a snake hepes-NaOH, 0.15 M NaCl, pH 7.35 containing 0.5
venom. From the literature it is known that several g/L bovine serum albumin (essentially fatty acid
snake venom proteases are inhibited by a2M [17, free; Sigma, Bornem, Belgium). Buffer B: buffer
18]. In vivo it is important to neutralize venom A containing additional EDTA (20 mM), pH 7.90.
proteolytic activity to minimize hemorrhagic effects
1.2. Plasmaafter snake envenomation. Recently, the isolation
and purification of an a2M-specific metalloprotease
from Crotalus basiliscus has been published by Svo- Plasma was prepared by collecting nine parts of
blood (from 10 healthy volunteers) on one part ofboda et al. [19]. This enzyme has no thrombin-
like activity and does not activate factor X and 0.13 M trisodium citrate. Following centrifugation
at 900g (158C, 10 minutes) and 10,000g (158C, 10plasminogen.
In this article, we describe the application of hy- minutes) the obtained plasma was pooled and cen-
trifuged at 48C for 1 hour at 23,000g; this plasmadroxylamine and the metalloprotease in the contin-
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was aliquoted and stored at 2808C. Plasma was basiliscus was a gift of Drs. M. Janssen and M.
Gempeler (Pentapharm; Basel, Switzerland). Adefibrinated by mixing an aliquot of plasma with
1/50 volume of 50 U/mL of Arwint (Knoll; Lud- stock solution was prepared by dissolving 1.488
mg of lyophilized protein in 1 mL distilled water,wigshafen, Germany), letting a clot form for 10
minutes at 378C. The fibrin clot was removed by aliquots of 100 mL were stored at 2808C. Plasma
was incubated with 1/15 volume of protease A forwinding it on a plastic spatula.
15 minutes at 378C.
1.3. Proteins
1.4. Manual Determination of
Thrombin Generation in PlasmaRecombinant human tissue factor (180 ng/mL)
(Dade; Düdingen, Switzerland) was used as a trig-
ger for coagulation. Purified a2M inactivating pro- This method is described in full detail by Hemker
et al. [3]. Briefly, to 240 mL plasma were added 40tease (protease A [19]) from the venom of Crotalus
Fig. 1. Thrombin generation
curves obtained by subsam-
pling. (A) The influence of
25 mM HO-NH2 on thrombin
generation. (Filled squares,
measured amidolytic activity
curve (control); open squares,
calculated free thrombin
curve (control); filled trian-
gles, measured amidolytic ac-
tivity curve (25 mM HO-
NH2); open triangles, calcu-
lated free thrombin curve (25
mM HO-NH2). (B) The influ-
ence of 3.5 mM protease A on
thrombin generation. (Filled
squares, measured amidolytic
activity curve (control); open
squares, calculated free throm-
bin curve (control); filled tri-
angles, measured amidolytic
activity curve (3.5 mM prote-
ase A); open triangles, calcu-
lated free thrombin curve
(3.5 mM protease A). The
curves shown in A were mea-
sured in plasma triggered
with a tissue factor concen-
tration of 6 ng/mL. Every 12
seconds a sample was drawn
to measure thrombin activ-
ity. At high thrombin activity
the reaction was stopped
after 30 seconds to 1 minute,
to prevent exhaustion of the
substrate. Curves in B were
measured as described in Ma-
terials and Methods.
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Table 1. Inhibition of the endogenous thrombin potential by international standard heparin in defibrin-
ated and non-defibrinated plasma
Defibrinated plasma
Calculated from
curve control Calculated from Calculated from
Heparin (25 mM HO-NH2) curve protease A/GPRP curve HO-NH2/GPRP
ISH U/mL Inhibition (%) Inhibition (%) Inhibition (%)
Non-defibrinated plasma
0 0 (0) 0 0
0.2 18.8 (23.6) 20.1 8.1
0.3 30.2 (30.6) 28.8 16.4
0.5 51.2 (51.7) 49.4 29.4
0.8 69.2 (72.1) 66.7 44.9
0.1 72 (79.4) 73.3 52.9
0.125 80.2 (86.1) 78 59.9
Non-defibrinated plasma
Measured as
Measured as endpoint protease
endpoint control A/GPRP
Inhibition (%) Inhibition (%)
0 0 0
0.2 18.7 22.5
0.3 30.2 30.5
0.5 51.5 51.6
0.8 69.2 67.5
0.1 71.9 71.6
0.125 80.1 76.7
HO-NH2/GPRP: plasma incubated with hydroxylamine (25 mM) and polymerization inhibitor H-Gly-Pro-Arg-Pro-OH (1.5 mg/mL), protease
A/GPRP: plasma incubated with protease A (3.5 mM) and polymerization inhibitor H-Gly-Pro-Arg-Pro-OH (1.0 mg/mL).
The inhibition of the ETP by heparin in the presence of hydroxylamine (25 mM) in defibrinated plasma is given by the values between brackets.
mL buffer A (containing the substance to be tested) (150 mM)/GPRP (9 mg/mL) or protease A (0.40
mg/mL)/GPRP (6 mg/mL) were pipetted into afollowed by 20 mL phospholipid vesicles DOPC/
DOPS 80/20 (20 mM). Thrombin generation was cuvette ring and incubated at 378C for 5 and 15
minutes, respectively. Then 20 mL of start reagentstarted at zero time by adding 60 mL tissue factor
(1/40) in 0.1 M CaCl2. At regular time intervals (10 mL tissue factor (undiluted), 5 mL 0.4 M CaCl2
and 5 mL 12 mM Msc-Val-Arg-pNA) was added.samples of 10 mL were subsampled into 490 mL
buffer B containing S2238 (200 mM) to determine The change in optical density was monitored at
405 nm every 30 seconds for 15 minutes.thrombin activity. After 2 minutes the reaction was
stopped by adding 300 mL 1M citric acid. The opti-
cal density was read at 405 nm and the amidolytic
activity was calculated. 2. Results and Discussion
The first purpose of this study was to determine1.5. Continuous Registration
whether hydroxylamine or protease A were ableof Thrombin Generation Curves
to inactivate a2M in plasma to reduce the residual
amidolytic activity of the a2M-IIa complex and toThe continuous thrombin assay was adapted to a
Cobas Fara laboratory automaton as described by test their applicability in the continuous thrombin
assay, and thereby to check any influence onWielders et al. [21]. In this study the following
conditions were used: 80 mL plasma sample (75 mL thrombin generation and inhibition processes. A
further goal was to evaluate whether hydroxyl-plasma and 5 mL buffer A containing the sub-
stances to be tested) and 20 mL of hydroxylamine amine or protease A could be used in non-defibrin-
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Fig. 2. Optical density curves
measured in defibrinated
plasma. (Filled squares, con-
trol; filled triangles, 25 mM
HO-NH2; filled circles, 3.5
mM protease A).
ated plasma, in this way making the time consum- or an acyl-enzyme [24,25], can be dissociated in
the presence of nucleophiles [26]. Fish and Björking defibrination of plasma redundant.
Plasma was incubated with hydroxylamine (25 [27] described that incubation of the thrombin-AT
III complex with 2 M hydroxylamine resulted aftermM, 5 minutes at 378C) and a significant reduction
of the residual amidolytic activity of a2M-IIa was 30 minutes in 15% to 20% free active thrombin
and reactive-site-loop-cleaved AT-III. We foundobserved (Figure 1A). The interaction between hy-
droxylamine and a2M was studied by Lambin et that AT-III activity in the presence of heparin is
not influenced by hydroxylamine (Table 1). Theal. [16] in a purified system. They found that hy-
droxylamine-treated a2M partially retained its ac- bridging of AT-III to thrombin by heparin creates
additional binding sites that enhance the stabilitytivity. However, complex formation between
thrombin and a2M was not prevented by hydroxyl- of the AT-III thrombin complex.
The optical density curve measured in hydroxyl-amine as observed by the reduced but persistent
amidolytic activity. Increasing the hydroxylamine amine treated plasma is shown in Figure 2 and
differs only in a reduction of the amidolytic end-concentration (100 mM) or the incubation time (2
hours) did result in a prolonged lag phase and level from the control plasma.
When plasma was incubated with the metallo-alterations of the thrombin peak instead in a zero
amidolytic endlevel. protease purified from the venom of Crotalus ba-
siliscus (protease A) [19], the free thrombin curveHydroxylamine, however, increases the half-life
of thrombin in plasma since it disturbs the interac- was obtained directly (Figure 1B) (this was also
observed by Hemker et al. [3] in a2M-deficienttion of AT-III with thrombin. This results in a
higher thrombin peak compared to the control plasma obtained by immunodepletion). Protease
A titrates a2M from plasma without disturbingplasma (Figure 1A). AT-III acts as a pseudosub-
strate for thrombin. The arginine393 residue at P1 thrombin generation or AT-III mediated inhibition
of thrombin, and the measured thrombin genera-of the reactive-site loop interacts with the active
site of thrombin to meet its primary specificity [22]. tion curve overlaps the calculated free thrombin
curve. The optical density curve obtained from pro-The formed intermediate, either tetrahedral [23]
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Fig. 3. Optical density curves
measured in non-defibrin-
ated plasma. (Filled squares,
control (defibrinated); filled
triangles, HO-NH2 (25 mM)/
GPRP (1.5 mg/mL); filled cir-
cles, protease A (3.5 mM)/
GPRP (1.0 mg/mL)). The
slope of the optical density
curve calculated after 15 min-
utes is: 12.9 mOD/min, con-
trol; 2.9 mOD/min, hydroxyl-
amine; and 0.8 mOD/min in
the presence of protease A.
tease A-treated plasma shows an almost zero end- ization inhibitors such as H-Gly-Pro-Arg-Pro-OH
[29, 30] and H-Gly-Pro-Arg-Pro-Ala-NH2 [31] pre-level of the amidolytic activity (Figure 2). In princi-
pal, the jump in optical density could be used as vent the occurrence of turbidity in non-defibrin-
ated plasma during thrombin generation at a con-a measure for the amount of thrombin formed and
thus representing the ETP. centration of 4 mg/mL (~10 mM). The successful
application of H-Gly-Pro-Arg-Pro-OH as fibrinThese results prompted us to test hydroxylamine
and protease A in non-defibrinated plasma. Since polymerization inhibitor was recently reported by
Prasa et al. [32]. In the presence of hydroxylaminehydroxylamine could be used as pseudosubstrate
for factor XIIIa and protease A was said to hy- or protease A the concentration of these polymer-
ization inhibitors could be reduced to 1.5 and 1.0drolyze the fibrinogen Aa and Bb chain [19], it
was hoped that fibrin polymerization could be post- mg/mL, respectively.
Optical density curves in non-defibrinatedponed to the end of the optical density recording.
An earlier report from Retzios and Markland de- plasma are given in Figure 3. Under these condi-
tions, the optical density curve of proteasescribes the purification and characterization of
three fibrino(geno)lytic enzymes from the venom A-treated plasma in the presence of 1 mg/mL
H-Gly-Pro-Arg-Pro-OH showed a zero amidolyticof Crotalus basiliscus basiliscus [28]. They describe
a metalloprotease, Cbfib 1.2, with a Mw of 23,500 endlevel. In hydroxylamine treated plasma, a small
residual amidolytic activity persists. More impor-and pI 4.7 which could be identical to protease A
(Mw: 23,400 and pI 4.8). An activity on a2M was, tant, however, hydroxylamine/GPRP reduces the
anticoagulant activity of heparin/AT-III signifi-however, not described. Defibrination of plasma
is a time-consuming process and we sought ways cantly (Table 1) in contrast to the protease A/
GPRP system (Table 1, Figure 4). The latter systemto circumvent this extra step. Our first attempt was
to measure thrombin generation in non-defibrin- allows the ETP determination as an endpoint mea-
surement of the optical density. We are currentlyated plasma in the presence of hydroxylamine or
protease A alone, but this did not lead to correct investigating the feasibility of measuring the ETP
under these experimental conditions.thrombin generation curves. The fibrin polymer-
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Fig. 4. Optical density curves
in non-defibrinated heparin-
ized plasma in the presence of
protease A (3.5 mM)/GPRP
(1.0 mg/mL). Thrombin gen-
eration is measured in plasma
with an increasing amount of
standard heparin. The jump
in optical density is a measure
for the ETP (Table 1). (Filled
squares, control; open squares,
0.02; filled triangles, 0.03;
open triangles, 0.05; filled cir-
cles, 0.08; open circles, 0.10;
open diamonds, 0.125 U ISH/
mL.) The slope of the optical
density curve calculated after
15 minutes is: 0.8 mOD/min,
control; 0.5, 0.5, 0.2, 0.3, 0.4,
and 0.3 mOD/min at the sev-
eral heparin concentrations.
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tic activity. In protease A-treated plasma, the mea- 10313–8.
sured thrombin generation curve leads directly to 3. Hemker HC, Willems GM, Béguin S. A com-
the free thrombin curve. We extended the method puter assisted method to obtain the prothrom-
of the continuous thrombin generation assay for bin activation velocity in whole plasma inde-
measurement in non-defibrinated plasma. Finally, pendent of thrombin decay processes. Thromb
we show that the determination of the ETP could Haemostas 1986;56:9–17.
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1.9Å crystal structure of D-Phe-Pro-Arg-chlo-S. Continuous registration of thrombin genera-
romethylketone-inhibited human a-thrombin:tion in plasma, its use for the determination
Structure analysis, overall structure, electro-of the thrombin potential. Thromb Haemostas
1993;70:617–24. static properties, detailed active-site geometry
168 D.T.S. Rijkers et al./Thrombosis Research 89 (1998) 161–169
and structure function relationships. Protein rhagic metalloproteinases with human a2-
macroglobulin. Biochemistry 1990;29:1069–74.Sci 1992;1:426–71.
8. Rijkers DTS, Hemker HC, Tesser GI. Synthe- 19. Svoboda P, Meier J, Freyvogel TA. Purifica-
tion and characterisation of three a2-antiplas-sis of peptide p-nitroanilides mimicking fibrin-
ogen- and hirudin-binding to thrombin, design min and a2-macroglobulin inactivating en-
zymes from the venom of the Mexican westof slow reacting thrombin substrates. Int J Pep-
tide Protein Res 1996;48:182–93. coast rattlesnake (Crotalus basiliscus). Toxicon
1995;33:1331–46.9. Rijkers DTS, Woodhams B, Béguin S, Tesser
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